Please login to the form below

Not currently logged in


This page shows the latest Synribo news and features for those working in and with pharma, biotech and healthcare.

Pfizer faces NICE rejection for cancer drug Bosulif

Pfizer faces NICE rejection for cancer drug Bosulif

and Teva's Synribo (omacetaxine) were priced at "astronomical" levels in the US.

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
11 London

We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....